New tentative approval for Watson Labs drug dienogest; estradiol valerate

Dienogest; estradiol valerate is the generic ingredient in one branded drug marketed by Bayer Hlthcare
and is included in one NDA. There are four patents protecting this compound.

This ingredient has ninety-four patent family members in forty-three countries.

Three suppliers are listed for this compound. There is one tentative approval for this compound.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

Which pharmaceutical companies have the most drug patents in South Africa?

This chart shows the pharmaceutical companies with the most patents in South Africa.

Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.

For a global perspective, see the Drug companies with the greatest global patent coverage.

The companies with the greatest patent coverage in South Africa are:

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent expiration for Merck Sharp drug ASMANEX TWISTHALER

Annual Drug Patent Expirations for ASMANEX+TWISTHALER
Annual Drug Patent Expirations for ASMANEX+TWISTHALER

Asmanex Twisthaler is a drug marketed by Merck Sharp Dohme
and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug.

The generic ingredient in ASMANEX TWISTHALER is mometasone furoate. Two suppliers are listed for this compound. Additional details are available on the mometasone furoate profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New tentative approval for Watson Labs drug dienogest; estradiol valerate

Dienogest; estradiol valerate is the generic ingredient in one branded drug marketed by Bayer Hlthcare
and is included in one NDA. There are four patents protecting this compound.

This ingredient has ninety-four patent family members in forty-three countries.

Three suppliers are listed for this compound. There is one tentative approval for this compound.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

Which pharmaceutical companies have the most SPCs in Lithuania?

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Lithuania.

SPCs are used in European Union and select others to encourage pharmaceutical innovation by
compensating for the long time needed to obtain regulatory approval for drugs. SPCs
come into force only after the corresponding general patent expires, and normally have a maximum lifetime of 5 years.

The total combined duration of market exclusivity of a general patent and SPC cannot normally exceed 15 years, but a six-month extention
may be obtained by responding to a request for pediatric trials.

For a different perspective, see the drug companies with SPCs in the most countries

The pharma companies with the most SPCs in Lithuania are:

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent for Merck Sharp drug DUTREBIS

Annual Drug Patent Expirations for DUTREBIS
Annual Drug Patent Expirations for DUTREBIS

Dutrebis is a drug marketed by Merck Sharp Dohme
and is included in one NDA. There are five patents protecting this drug.

This drug has eigthy-three patent family members in forty-one countries.

The generic ingredient in DUTREBIS is lamivudine; raltegravir potassium. Additional details are available on the lamivudine; raltegravir potassium profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent for Merck Sharp drug ISENTRESS HD

Annual Drug Patent Expirations for ISENTRESS+HD
Annual Drug Patent Expirations for ISENTRESS+HD

Isentress Hd is a drug marketed by Merck Sharp Dohme
and is included in one NDA. It is available from ten suppliers. There are five patents protecting this drug.

This drug has one hundred and two patent family members in forty-three countries.

The generic ingredient in ISENTRESS HD is raltegravir potassium. Ten suppliers are listed for this compound. Additional details are available on the raltegravir potassium profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent for Merck Sharp drug ISENTRESS

Annual Drug Patent Expirations for ISENTRESS
Annual Drug Patent Expirations for ISENTRESS

Isentress is a drug marketed by Merck Sharp Dohme
and is included in three NDAs. It is available from ten suppliers. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has eigthy-three patent family members in forty-one countries.

The generic ingredient in ISENTRESS is raltegravir potassium. Ten suppliers are listed for this compound. Additional details are available on the raltegravir potassium profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New tentative approval for Watson Labs drug dienogest; estradiol valerate

Dienogest; estradiol valerate is the generic ingredient in one branded drug marketed by Bayer Hlthcare
and is included in one NDA. There are four patents protecting this compound.

This ingredient has ninety-four patent family members in forty-three countries.

Three suppliers are listed for this compound. There is one tentative approval for this compound.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

Which pharmaceutical drugs have the most drug patents in European Patent Office?

This chart shows the drugs with the most patents in European Patent Office.

Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.

The companies with the greatest patent coverage in European Patent Office are:

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com